Research

Mixed

The Elipse swallowable intragastric balloon does not produce clinically significant weight loss or diabetes control in patients with obesity class 1-2 and type 2 diabetes when used in a real-world setting with standard nutritional follow-up.

If you have obesity and type 2 diabetes, this specific swallowable balloon is not a reliable standalone solution for significant weight loss in a standard healthcare setting. It resulted in only ~4% weight loss at 16 weeks, which is minimal compared to surgical options. It may be considered only if you strictly adhere to intensive dietary counseling and accept modest results, but it is not a substitute for more effective interventions.

ModerateRefutesLOW confidence
This first Scandinavian real-world clinical trial with a new minimally invasive intragastric balloon system demonstrated good feasibility, but did not confirm expected efficacy for weight loss and diabetes control.
Christer Julseth Tønnesen et al. · Scandinavian Journal of Gastroenterology · 2021

Why this rating

Small sample size (n=19), single-arm pilot design, short duration, and lack of control group limit generalizability.

Source

A novel intragastric balloon for treatment of obesity and type 2 diabetes. A two-center pilot trial

Christer Julseth Tønnesen et al. · Scandinavian Journal of Gastroenterology · 2021

DOI 10.1080/00365521.2021.1994641

case_series · n=19Cited 15×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →